by NeOnc Technologies | Aug 5, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Releases | August 5, 2024 > NeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with...
by NeOnc Technologies | Jul 24, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Release | July 24, 2024 > NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212 NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’...
by NeOnc Technologies | Jun 26, 2024 | Press Releases
Main > Archives for NeOnc Technologies Press Release | June 26, 2024 > NeOnc Technologies Completes $18.5 Million Financing NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel...
by NeOnc Technologies | May 15, 2024 | Press Releases
Main > Archives for NeOnc Technologies NEO100 Research | May 15, 2024 > NeOnc Receives Breakthrough Medical Technology Achievement Award from CIS LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical...
by NeOnc Technologies | Apr 4, 2023 | Press Releases
Main > You searched for amir NEO100 Research | APRIL 04, 2023 > NeOnc’s CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’ Los Angeles, CA, Chicago, IL, London, UK, April 4, 2023 – NeOnc Technologies Holdings Inc., a...
by NeOnc Technologies | Mar 6, 2023 | Press Releases
Main > You searched for IDH1 NEO100 Research | MARCH 6, 2023 > NeOnc Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100® Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and...